These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31765065)

  • 1. BRAF molecular testing in cytopathology: Implications for diagnosis, prognosis, and targeted therapeutics.
    Bergdorf KN; Lee LA; Weiss VL
    Cancer Cytopathol; 2020 Jan; 128(1):9-11. PubMed ID: 31765065
    [No Abstract]   [Full Text] [Related]  

  • 2. Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm.
    Turski ML; Vidwans SJ; Janku F; Garrido-Laguna I; Munoz J; Schwab R; Subbiah V; Rodon J; Kurzrock R
    Mol Cancer Ther; 2016 Apr; 15(4):533-47. PubMed ID: 27009213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
    Lin PS; Semrad TJ
    Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
    Peng SB; Henry JR; Kaufman MD; Lu WP; Smith BD; Vogeti S; Rutkoski TJ; Wise S; Chun L; Zhang Y; Van Horn RD; Yin T; Zhang X; Yadav V; Chen SH; Gong X; Ma X; Webster Y; Buchanan S; Mochalkin I; Huber L; Kays L; Donoho GP; Walgren J; McCann D; Patel P; Conti I; Plowman GD; Starling JJ; Flynn DL
    Cancer Cell; 2015 Sep; 28(3):384-98. PubMed ID: 26343583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation and location important in cancer treatment.
    Lewis R
    Lancet Oncol; 2015 Oct; 16(13):e482. PubMed ID: 26321213
    [No Abstract]   [Full Text] [Related]  

  • 6. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
    Dankner M; Rose AAN; Rajkumar S; Siegel PM; Watson IR
    Oncogene; 2018 Jun; 37(24):3183-3199. PubMed ID: 29540830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is optimal first-line treatment of unresectable or advanced BRAF-mutant melanoma?
    Atkins MB
    Clin Adv Hematol Oncol; 2016 Jun; 14(6):417-9. PubMed ID: 27379810
    [No Abstract]   [Full Text] [Related]  

  • 8. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
    Capovilla M
    Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma.
    Cohen JV; Sullivan RJ
    Clin Cancer Res; 2019 Oct; 25(19):5735-5742. PubMed ID: 30992297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents.
    Rossi A; Roberto M; Panebianco M; Botticelli A; Mazzuca F; Marchetti P
    Eur J Pharmacol; 2019 Nov; 862():172621. PubMed ID: 31446019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition.
    Amaral T; Sinnberg T; Meier F; Krepler C; Levesque M; Niessner H; Garbe C
    Eur J Cancer; 2017 Mar; 73():93-101. PubMed ID: 28162869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF mutation testing in clinical practice.
    Ziai J; Hui P
    Expert Rev Mol Diagn; 2012 Mar; 12(2):127-38. PubMed ID: 22369373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Path Forward for RAF Therapies: Inhibition of Monomers and Dimers.
    Kortum RL; Morrison DK
    Cancer Cell; 2015 Sep; 28(3):279-81. PubMed ID: 26373275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor heterogeneity and strategies to overcome kinase inhibitor resistance in cancer: lessons from melanoma.
    Rebecca VW; Smalley KS
    Expert Opin Investig Drugs; 2011 Feb; 20(2):137-40. PubMed ID: 21235427
    [No Abstract]   [Full Text] [Related]  

  • 15. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
    Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
    Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. American Society of Clinical Oncology Developing First Clinical Trial.
    Brower V
    J Natl Cancer Inst; 2015 Nov; 107(11):djv356. PubMed ID: 26538625
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutic strategies for inhibiting oncogenic BRAF signaling.
    Halilovic E; Solit DB
    Curr Opin Pharmacol; 2008 Aug; 8(4):419-26. PubMed ID: 18644254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological challenges of BRAF inhibitor therapy.
    Puzanov I; Burnett P; Flaherty KT
    Mol Oncol; 2011 Apr; 5(2):116-23. PubMed ID: 21393075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
    Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
    Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
    Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
    J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.